BCBS Michigan scores $147M in savings through biosimilars

(By: Elizabeth Casolo for Becker’s Hospital Review)

BCBS Michigan saved $67 million and $80 million in 2024 and 2025, respectively, through biosimilar use, the insurer reported Feb. 17.

The company began moving members from Humira and Stelara to alternatives like Simlandi and Yesintek in 2025. Currently, 99% of members needing Humira and Stelara are now on biosimilars. Instead of Humira’s list price of $10,400 per month, members access Simlandi for under $1,000 per month, generating savings of 90% or more. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.